Research Letter| Volume 38, ISSUE 10, P2318-2323, October 2016

A Review of Ferric Pyrophosphate Citrate (Triferic) Use in Hemodialysis Patients

Published:September 27, 2016DOI:



      The objective of this short review is to evaluate the efficacy of ferric pyrophosphate citrate and to determine its place in therapy based on the current published literature.


      A literature search was conducted and pared down to yield 4 placebo controlled Phase II and III clinically relevant trials.


      Ferric pyrophosphate citrate is a new intradialytic iron supplementation product that has been found to reduce the dose of erythropoiesis-stimulating agents and intravenous iron supplementation and to increase serum ferritin concentrations.


      This agent may be administered to patients with stage 5 chronic kidney disease receiving hemodialysis as a new iron supplementation option to maintain hemoglobin, transferrin saturation, and ferritin concentrations.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Kidney Diseases Improving Global Outcomes: Clinical Practice Guidelines for Anemia in Chronic Kidney Disease. Accessed July 26, 2015

        • Fishbane S.N.
        • Maesaka J.K.
        Iron management in end-stage renal disease.
        Am J Kidney Dis. 1997; 29: 319-333
        • Roser-Zvi B.
        • Gafter-Gvilli A.
        • Paul M.
        • et al.
        Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systemic review and meta-analysis.
        Am J Kidney Dis. 2008; 52: 897-906
        • Pai A.B.
        • Boyd A.V.
        • McQuade C.R.
        • et al.
        Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis.
        Pharmacotherapy. 2007; 27: 343-350
        • Bailie G.R.
        • Johnson C.A.
        • Mason N.A.
        Parenteral iron use in the management of anemia in end-stage renal disease patients.
        Am J Kidney Dis. 2000; 35: 1-12
        • Gupta A.
        • Amin N.B.
        • Besarab A.
        • et al.
        Dialysate iron therapy: infusion of soluble ferric pyrophosphate via the dialysate during dialysis.
        Kidney Int. 1999; 55: 1891-1898
        • Konopka K.
        • Mareschal J.C.
        • Crichton R.R.
        Iron transfer from transferrin to ferritin mediated by polyphosphate compounds.
        Biochim Biophys Acta. 1981; 677: 417-423
        • Morgan E.H.
        Iron exchange between transferrin molecules mediated by phosphate compounds and other cell metabolites.
        Biochim Biophys Acta. 1977; 499: 169-177
        • Nilsen T.
        • Romslo I.
        Pyrophosphate as a ligand for delivery of iron to isolated rat-liver mitochondria.
        Biochim Biophys Acta. 1984; 766: 233-239
        • Gupta A.
        • Crumbliss A.L.
        Treatment of iron deficiency anemia: are monomeric iron compounds suitable for parenteral administration?.
        J Lab Clin Med. 2000; 136: 371-378
        • Auerbach M.
        • Coyne D.
        • Ballard H.
        Intravenous iron: from anathema to standard of care.
        Am J Hematol. 2008; 83: 580-588
        • Gupta A.
        • Lin V.
        • Guss C.
        • et al.
        Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients.
        Kidney Int. 2015; 88: 1187-1194
        • Fishbane S.N.
        • Singh A.K.
        • Cournoyer S.H.
        • et al.
        Ferric pyrophosphate citrate (Triferic™) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients.
        Nephrol Dial Transplant. 2015; 30: 2019-2026
      2. U.S. National Institutes of Health. Accessed July 6, 2016.

        • Park S.E.
        • Twardowski Z.J.
        • Moore H.L.
        • et al.
        Chronic administration of iron dextran into the peritoneal cavity of rats.
        Perit Dial Int. 1997; 17: 179-185